NCT00477191View on ClinicalTrials.gov

Effects of TNF-alpha Antagonism (Etanercept) in Patients With the Metabolic Syndrome and Psoriasis

NATerminatedINTERVENTIONAL

Enrollment

18

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions

PsoriasisMetabolic SyndromeHyperlipidemiaObesityHypertension

Interventions

DRUG

Etanercept

TNF-alpha antagonist 50 mg twice a week x 3 mos and the 50 mg once a week for 3 months.

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Amgen

INDUSTRY

lead

Massachusetts General Hospital

OTHER

NCT00477191 - Effects of TNF-alpha Antagonism (Etanercept) in Patients With the Metabolic Syndrome and Psoriasis | Biotech Hunter | Biotech Hunter